Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F., Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib, «ANTI-CANCER DRUGS», 2024, 35, pp. 86 - 88 [Scientific article]
Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A., From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC), «DIAGNOSTICS», 2024, 14, Article number: 48 , pp. 1 - 29 [Scientific article]Open Access
De Giglio A.; Di Federico A.; Gariazzo E.; Metro G., Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy, «MED», 2024, 5, pp. 1 - 3 [Scientific article]
De Giglio A.; Deiana C.; Di Federico A., Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2023, 149, pp. 1835 - 1847 [Scientific article]Open Access
Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A., Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review, «LUNG CANCER: TARGETS AND THERAPY», 2023, 14, pp. 11 - 25 [Scientific article]
Scalera S.; Ricciuti B.; Mazzotta M.; Calonaci N.; Alessi J.V.; Cipriani L.; Bon G.; Messina B.; Lamberti G.; Di Federico A.; Pecci F.; Milite S.; Krasniqi E.; Barba M.; Vici P.; Vecchione A.; De Nicola F.; Ciuffreda L.; Goeman F.; Fanciulli M.; Buglioni S.; Pescarmona E.; Sharma B.; Felt K.D.; Lindsay J.; Rodig S.J.; De Maria R.; Caravagna G.; Cappuzzo F.; Ciliberto G.; Awad M.M.; Maugeri-Sacca M., Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma, «ANNALS OF ONCOLOGY», 2023, 34, pp. 275 - 288 [Scientific article]
Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A., Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond, «BIOMOLECULES», 2023, 13, Article number: 1803 , pp. 1 - 15 [Scientific article]Open Access
Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M., Peripheral nervous system adverse events associated with immune checkpoint inhibitors, «JOURNAL OF NEUROLOGY», 2023, 270, pp. 2975 - 2986 [Scientific article]Open Access
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis, «JOURNAL OF THE NATIONAL CANCER INSTITUTE», 2023, 115, pp. 29 - 42 [Scientific article]
Di Federico A.; Ricciotti I.; Favorito V.; Michelina S.V.; Scaparone P.; Metro G.; De Giglio A.; Pecci F.; Lamberti G.; Ambrogio C.; Ricciuti B., Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer, «CURRENT ONCOLOGY REPORTS», 2023, 25, pp. 1017 - 1029 [Scientific article]
Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio, The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma, «CURRENT ONCOLOGY», 2023, 30, pp. 4754 - 4766 [Scientific article]Open Access
Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G., Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease, «DRUGS IN CONTEXT», 2022, 11, Article number: A1 , pp. 1 - 10 [Scientific article]
De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G., Advanced non-small-cell lung cancer: how to manage non-oncogene disease, «DRUGS IN CONTEXT», 2022, 11, Article number: 2022-2-4 , pp. 1 - 14 [Scientific article]Open Access
Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G., Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 361 - 369 [Scientific article]
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi, Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?, «FUTURE ONCOLOGY», 2022, 905, pp. 1 - 12 [Scientific article]
